Exploring new biomarkers for diagnosing and treating neuroendocrine tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter observational study investigates new biomarkers, including immune profiling, angiogenetic markers, and circular RNAs from tumor-educated platelets (TEPs), to improve diagnosis and treatment response evaluation in patients with neuroendocrine neoplasms (NENs). The study aims to address the limitations of existing tumor markers by utilizing liquid biopsies, which may provide a less invasive method for cancer diagnostics. By analyzing immune cell profiles and TEPs, the research seeks to enhance understanding of the immune status in NEN patients and identify more effective diagnostic tools.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically-proven NENs, locally advanced or metastatic, originating from pulmonary or gastro-entero-pancreatic (GEP) tract, candidate to first line medical therapy (study group);
* Patients affected by other non-malignant endocrine disease, e.g. benign thyroid disfunction (control group).

Exclusion Criteria:

* Severe chronic kidney disease (stage 4-5);
* Clinical or laboratory signs of significant respiratory, cardiological and hepatobiliary disease;
* Other non-neuroendocrine malignancies.

Where it's running

• Andrea M Isidori
  Rome, Italy, Italy Recruiting

Study contacts

• Principal investigator: Andrea M Isidori, MD, PhD — Department of Experimental Medicine, Sapienza University of Rome
• Study coordinator: Andrea M Isidori, MD, PhD
• Email: andrea.isidori@uniroma1.it
• Phone: +390649970540

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Investigating the impact of somatostatin analogues on tumor dose during radionuclide therapy

  This study is testing if stopping or continuing long-acting somatostatin treatment affects how well radionuclide therapy works for adults with neuroendocrine tumors.

  Recruiting Phase 2/3 The Netherlands Cancer Institute · Amsterdam · NCT06855095

• Comparing two doses of Everolimus for treating neuroendocrine tumors

  This study is testing whether a lower dose of Everolimus can effectively treat patients with advanced neuroendocrine tumors while causing fewer side effects compared to a higher dose.

  Recruiting at 2 sites Phase 2 AC Camargo Cancer Center · São Paulo, São Paulo and 1 other locations · NCT06472388

• Customized Lutetium-177 treatment for neuroendocrine tumors

  This study is testing if a personalized dose of Lutetium-177 can improve treatment results for adults with hard-to-treat neuroendocrine tumors compared to standard treatment.

  Recruiting Phase 2 University of Iowa · Iowa City, Iowa · NCT06395402

• CTX-471 for NCAM-positive metastatic neuroendocrine tumors

  A phase 2 trial is testing CTX-471 in adults with NCAM (CD56) positive metastatic neuroendocrine tumors that have progressed after standard therapy.

  Recruiting at 2 sites Phase 2 Compass Therapeutics · St Louis, Missouri and 1 other locations · NCT07684170

• Testing a new treatment for advanced neuroendocrine tumors

  This study is testing a new treatment combining a virus with two cancer drugs to see if it helps people with advanced neuroendocrine tumors feel better and tolerate the treatment well.

  Recruiting Phase 1 University of Miami · Miami, Florida · NCT06889493

• Using a new type of PET scanner for imaging prostate cancer and related conditions

  This study is testing a new type of PET scanner to see if it can better detect early signs of prostate cancer and related conditions in patients.

  Recruiting Jagiellonian University · Krakow · NCT06242119

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.